The real effects of Wegovy: what the evidence shows

The myth: Wegovy is simply an appetite suppressant you notice straight away

Most people starting Wegovy expect to feel an obvious change within a day or two. The reality is subtler. Semaglutide does reduce appetite, but its primary mechanism is signalling, it acts on GLP-1 receptors in the hypothalamus and gastrointestinal tract to change how your body registers fullness and hunger. You are unlikely to feel dramatically different after the first injection. What most people notice first is not a sudden disinterest in food but a quieter background noise of hunger: meals feel satisfying with less on the plate, and the pull to snack between them gradually weakens.

The titration schedule reinforces this. Treatment begins at a low dose specifically to let your body adjust; the therapeutic effects build as the dose increases over several months. Expecting dramatic results in week one sets people up to believe the medicine is not working when, in practice, it is doing exactly what it should. If you are concerned that Wegovy seems to be having no effect after a reasonable period, there is specific guidance on what to do if Wegovy is not working for you that covers the most common clinical reasons.

The NHS semaglutide medicines page gives a clear overview of how the medicine works and what to realistically expect.

What Wegovy's effects look like across the body, beyond the scale

Weight loss is the licensed purpose, but semaglutide's effects extend further. In cardiovascular trials (separate from the weight-management licence), semaglutide at this dose reduced the risk of major cardiovascular events in eligible adults. The MHRA has also granted a conditional approval, as of 3 July 2026, for Wegovy in metabolic-associated steatohepatitis (a form of fatty liver disease) reflecting how the medicine's effects reach tissue well beyond the gut. For weight management purposes, which is what Wegovy is licensed for in the UK, the effects that matter practically are reduced energy intake, steadier blood sugar regulation after meals, and a slower gastric emptying rate that prolongs the feeling of fullness.

Some of these effects touch areas people do not always expect. Hormonal changes linked to weight loss can affect the menstrual cycle; there is specific information available on how Wegovy can affect periods for those who want to understand that side of things. Reporting any unexpected effects through the MHRA Yellow Card scheme is encouraged, the data collected helps regulators track real-world outcomes for a medicine still under enhanced surveillance.

Side effects: the honest picture

Gastrointestinal effects are the most common. Nausea, loose stools, constipation, reflux and burping appear in a meaningful proportion of people, especially in the first few weeks and after each dose step up. For most, these settle. They are a direct consequence of the slowed gastric emptying that is also responsible for the medicine's effectiveness, the mechanism and the side effect are the same thing, working in different directions.

More serious effects are less common but worth knowing. The MHRA issued a Drug Safety Update in January 2026 flagging acute pancreatitis as an infrequent but potentially serious risk with GLP-1 medicines: severe stomach pain that radiates to the back, with or without vomiting, warrants urgent medical attention. Gallbladder problems, injection-site reactions, headache and fatigue are also listed. Some people notice an elevated temperature in the early days; if you are wondering whether a mild fever on Wegovy is normal, this is addressed separately. The first day of treatment has its own pattern too, the first 24 hours on Wegovy are worth reading about before your initial injection.

Wegovy is not recommended during pregnancy, while breastfeeding, or when actively trying to conceive. It is not licensed for anyone under 18. These are hard limits, not suggestions.

How much weight loss to expect, and when

The STEP 1 trial, published in the New England Journal of Medicine, reported an average body-weight reduction of around 15% over 68 weeks at the 2.4mg dose, against roughly 2.4% with placebo. That is a population average across thousands of participants, individual results vary considerably based on starting weight, adherence, lifestyle changes and clinical factors your prescriber will consider.

The timeline matters. Most measurable weight loss happens from around weeks 8–12 onwards as the dose escalates. For a detailed breakdown of the week-by-week trajectory, the time it takes for Wegovy to take effect is covered in full. Understanding when Wegovy starts to take effect for different people helps set realistic expectations before the medicine even arrives.

If you have read the evidence and want to understand whether semaglutide is clinically appropriate for you, check your eligibility with our prescribers, the consultation is free, and a real clinician reads your answers the same day.